Lupus News and Research RSS Feed - Lupus News and Research

Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]
Scientists identify how immune cells use two critical receptors to clear dead cells from the body

Scientists identify how immune cells use two critical receptors to clear dead cells from the body

In most of the tissues of the body, specialized immune cells are entrusted with the task of engulfing the billions of dead cells that are generated every day. [More]
LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced nearly $750,000 in Proof of Concept grants to Washington state for-profit and non-profit organizations to promote translation of health-related technologies from the laboratory to the commercial marketplace. [More]
Scientists make important breakthrough in fight against debilitating autoimmune diseases

Scientists make important breakthrough in fight against debilitating autoimmune diseases

Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue. [More]
Researchers find method to expand blood stem cells used to treat cancer patients

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. [More]
Rheumatologic diseases can initially present as neurological disorders, delay diagnosis for many months

Rheumatologic diseases can initially present as neurological disorders, delay diagnosis for many months

Lupus and other rheumatologic diseases can initially present as neurological disorders such as headaches and seizures, and thus delay diagnosis for many months, according to Loyola University Medical Center neurologists. [More]
Research roundup: Benefits of smaller practices; Rx price growth; fixing Medicare claims reviews

Research roundup: Benefits of smaller practices; Rx price growth; fixing Medicare claims reviews

The Centers for Medicare & Medicaid Services within the Department of Health and Human Services has taken steps to prevent its contractors from conducting certain duplicative postpayment claims reviews-;reviews of the same claims that are not permitted by the agency-;but CMS neither has reliable data nor provides sufficient oversight and guidance to measure and fully prevent duplication. [More]
Mortality predictors REVEALed for PAH in systemic sclerosis

Mortality predictors REVEALed for PAH in systemic sclerosis

Elderly men and patients with low baseline systolic blood pressure are among those at a particularly high risk of death from pulmonary arterial hypertension associated with systemic sclerosis, a US study has found. [More]
Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus. [More]
Black and Hispanic SLE patients are more likely to be readmitted than white patients

Black and Hispanic SLE patients are more likely to be readmitted than white patients

A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged. [More]
Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism. [More]
Researchers confirm for the first time that achalasia is autoimmune in origin

Researchers confirm for the first time that achalasia is autoimmune in origin

Achalasia is a rare disease - it affects 1 in 100,000 people - characterized by a loss of nerve cells in the esophageal wall. [More]

New version of drug successfully treats lupus in mice

Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases. [More]
Brain network measures placebo effects in Parkinson's disease patients

Brain network measures placebo effects in Parkinson's disease patients

Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. [More]
Investigators identify gene that underlies devastating autoinflammatory condition in children

Investigators identify gene that underlies devastating autoinflammatory condition in children

Investigators have identified a gene that underlies a very rare but devastating autoinflammatory condition in children. Several existing drugs have shown therapeutic potential in laboratory studies, and one is currently being studied in children with the disease, which the researchers named STING-associated vasculopathy with onset in infancy (SAVI). [More]
Researchers reveal molecular interplay between Roquin and RNA

Researchers reveal molecular interplay between Roquin and RNA

The Roquin protein, discovered in 2005, controls T-cell activation and differentiation by regulating the expression of certain mRNAs. In doing so, it helps to guarantee immunological tolerance and prevents immune responses against the body's own structures that can lead to autoimmune disease. [More]
Study to understand molecular interplay between Roquin and RNA to treat autoimmune diseases

Study to understand molecular interplay between Roquin and RNA to treat autoimmune diseases

Scientists at the Helmholtz Zentrum München, the Ludwig-Maximilians University of Munich (LMU) and the Technische Universität München (TUM) have moved an important step closer to understanding molecular mechanisms of autoimmune diseases. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Researchers find unique cell type that can protect against uveitis

Researchers find unique cell type that can protect against uveitis

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss. [More]
Study shows significantly increased risk of heart attack in patients with Sj-gren's syndrome

Study shows significantly increased risk of heart attack in patients with Sj-gren's syndrome

A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed a significantly increased risk of heart attack in patients with Sj-gren's syndrome (SjS), particularly in the first year following diagnosis. [More]